Journal of Basic Research in Medical Sciences
J Basic Res Med Sci
Volume 12, Issue 4 (9-2025)
jbrms 2025, 12(4): 64-76 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nikpour H, Seidkhani-Nahal A, Golshani S, Basati G. Evaluation of Serum Inosine, Hypoxanthine, and Carnitine as Ischemia Markers of Heart Disease. jbrms 2025; 12 (4) :64-76
URL: http://jbrms.medilam.ac.ir/article-1-964-en.html
URL: http://jbrms.medilam.ac.ir/article-1-964-en.html
Department of Clinical Biochemistry, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran , gholam.basati@gmail.com
Abstract: (14 Views)
Introduction: Heart disease (HD) is a major global death cause, with adenosine triphosphate metabolites, carnitine, and other biomarkers aiding in timely detection and disease prediction. This study aims to investigate the changes in inosine, hypoxanthine, and carnitine levels in the serum of ischemic HD patients and to examine the relationship of these components with the extent of coronary artery blockage, as well as for the detection of coronary artery disease (CAD).
Materials & Methods: In this cross-sectional and case-control study, from patients who underwent angiographic assessment for suspected CAD, 40 control subjects, 40 stable angina patients, 40 unstable angina patients, and 40 myocardial infarction patients were selected. Serum samples were collected, and the amounts of inosine, hypoxanthine, and carnitine were measured using an HPLC-UV-visible method. The differences of the three substances in the patients and their clinical importances were analyzed by SPSS V.22 (P < 0.05).
Results: The results of this study showed that the levels of inosine and hypoxanthine in patients were higher than those in the control group (P < 0.01), while the level of carnitine was lower than that in the control group (P = 0.04). Conversely, the concentration of carnitine in patients was lower than in the healthy control group, with respective concentrations of 31.84 (28.58-35.62), 34.01 (28.25-37.13), and 33.59 (28.58-38.87) µg/ml.
Conclusion: This study indicated that inosine and hypoxanthine could be effective and rapid discriminators, in comparison with other heart biomarkers, for the timely detection of HD.
Materials & Methods: In this cross-sectional and case-control study, from patients who underwent angiographic assessment for suspected CAD, 40 control subjects, 40 stable angina patients, 40 unstable angina patients, and 40 myocardial infarction patients were selected. Serum samples were collected, and the amounts of inosine, hypoxanthine, and carnitine were measured using an HPLC-UV-visible method. The differences of the three substances in the patients and their clinical importances were analyzed by SPSS V.22 (P < 0.05).
Results: The results of this study showed that the levels of inosine and hypoxanthine in patients were higher than those in the control group (P < 0.01), while the level of carnitine was lower than that in the control group (P = 0.04). Conversely, the concentration of carnitine in patients was lower than in the healthy control group, with respective concentrations of 31.84 (28.58-35.62), 34.01 (28.25-37.13), and 33.59 (28.58-38.87) µg/ml.
Conclusion: This study indicated that inosine and hypoxanthine could be effective and rapid discriminators, in comparison with other heart biomarkers, for the timely detection of HD.
Type of Study: Research |
Subject:
Clinical Biochemistry
Received: 2025/04/12 | Accepted: 2025/06/6 | Published: 2025/10/5
Received: 2025/04/12 | Accepted: 2025/06/6 | Published: 2025/10/5
References
1. Shahjehan RD, Sharma S, Bhutta BS. Coronary Artery Disease. 2024 Oct 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
2. Wilson PWF, O’Donnell CJ. Epidemiology of Chronic Coronary Artery Disease. In: de Lemos JA, Omland T, editors. Chronic Coronary Artery Disease: Elsevier; 2018. p. 1-15. doi:10.1016/B978-0-323-42880-4.00001-7.
3. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022;23(6):3346. doi: 10.3390/ijms23063346.
4. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23. doi: 10.1002/jcp.28350.
5. Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017;13(6):368-80. doi: 10.1038/nrneph.2017.51.
6. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis. 2016;109(12):708-715. doi: 10.1016/j.acvd.2016.04.002.
7. Gabara L, Jokhi P, Curzen N. Ischaemic heart disease: stable angina. Medicine. 2018;46(9):520-7. doi:10.1016/j.mpmed.2022.04.004.
8. Tang Y, Cai H, Zhan Z, Luo Y, Huang Y, Chen D, Chen B. Herbal medicine (zhishi xiebai guizhi decoction) for unstable angina: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(52):e13965. doi: 10.1097/MD.0000000000013965.
9. Yang X, Xiong X, Yang G, Wang J. Chinese patent medicine Xuefu Zhuyu capsule for the treatment of unstable angina pectoris: A systematic review of randomized controlled trials. Complement Ther Med. 2014;22(2):391-9. doi: 10.1016/j.ctim.2014.01.003.
10. Liu S, Wu J, Zhang D, Tan D. What are the best Salvia miltiorrhiza injection classes for treatment of unstable angina pectoris? A systematic review and network Meta-analysis. J Tradit Chin Med. 2018;38(3):321-338.
11. Sandoval Y, Apple FS, Smith SW. High-sensitivity cardiac troponin assays and unstable angina. Eur Heart J Acute Cardiovasc Care. 2018;7(2):120-128. doi: 10.1177/2048872616658591.
12. Wehrmacher WH, Bellows R. Unstable angina. Compr Ther. 2004;30(1):6-9. doi: 10.1007/s12019-004-0018-y.
13. Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020;17(1):9-21. doi: 10.1038/s41569-019-0233-y.
14. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial Infarction: Symptoms and Treatments. Cell Biochem Biophys. 2015;72(3):865-7. doi: 10.1007/s12013-015-0553-4.
15. Aydin S, Ugur K, Aydin S, Sahin İ, Yardim M. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019;15:1-10. doi: 10.2147/VHRM.S166157.
16. Ye XD, He Y, Wang S, Wong GT, Irwin MG, Xia Z. Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. Acta Pharmacol Sin. 2018;39(7):1155-1163. doi: 10.1038/aps.2018.37.
17. Farthing D, Xi L, Gehr L, Sica D, Larus T, Karnes HT. High-performance liquid chromatography (HPLC) determination of inosine, a potential biomarker for initial cardiac ischaemia, using isolated mouse hearts. Biomarkers. 2006;11(5):449-59. doi: 10.1080/13547500600800074.
18. Farthing DE, Farthing CA, Xi L. Inosine and hypoxanthine as novel biomarkers for cardiac ischemia: from bench to point-of-care. Exp Biol Med (Maywood). 2015;240(6):821-31. doi: 10.1177/1535370215584931. Epub 2015 May 8.
19. Lee BJ, Lin JS, Lin YC, Lin PT. Effects of L-carnitine supplementation on lipid profiles in patients with coronary artery disease. Lipids Health Dis. 2016;15:107. doi: 10.1186/s12944-016-0277-5.
20. Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr. 2009;89(1):71-6. doi: 10.3945/ajcn.2008.26251.
21. Fathizadeh H, Milajerdi A, Reiner Ž, Kolahdooz F, Chamani M, Amirani E, Asemi Z. The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Pharm Des. 2019;25(30):3266-3281. doi: 10.2174/1381612825666190830154336.
22. Cabral REL, Mendes TB, Vendramini V, Miraglia SM. Carnitine partially improves oxidative stress, acrosome integrity, and reproductive competence in doxorubicin-treated rats. Andrology. 2018;6(1):236-246. doi: 10.1111/andr.12426.
23. Lee BJ, Lin JS, Lin YC, Lin PT. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition. 2015;31(3):475-9. doi: 10.1016/j.nut.2014.10.001.
24. Moeinian M, Ghasemi-Niri SF, Mozaffari S, Abdollahi M. Synergistic effect of probiotics, butyrate and l-Carnitine in treatment of IBD. J Med Hypotheses Ideas. 2013;7(2):50-3. doi:10.1016/j.jmhi.2013.02.003.
25. Gülçin I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006;78(8):803-11. doi: 10.1016/j.lfs.2005.05.103.
26. Jeyaraj FT, Voruganti VS. Multifaceted role of inosine in complex diseases and human health. Nutr Rev. 2025 Feb 1;83(2): e506-e517. doi: 10.1093/nutrit/nuae029.
27. Barlett JE, Kotrlik J, Higgins C. Organizational Research: Determining Appropriate Sample Size in Survey Research. Inform Technol Learn Performance J. 2001;19(1):43-50.
28. Li K, Sun Q. Simultaneous determination of free and total carnitine in human serum by HPLC with UV detection. J Chromatogr Sci. 2010;48(5):371-4. doi: 10.1093/chromsci/48.5.371.
29. Jangaard N, Sarkisian L, Saaby L, Mikkelsen S, Lassen AM, Marcussen N, Thomsen JL, Diederichsen ACP, Thygesen K, Mickley H. Incidence, Frequency, and Clinical Characteristics of Type 3 Myocardial Infarction in Clinical Practice. Am J Med. 2017;130(7):862.e9-862.e14. doi: 10.1016/j.amjmed.2016.12.034.
30. Farthing D, Sica D, Gehr T, Wilson B, Fakhry I, Larus T, Farthing C, Karnes HT. An HPLC method for determination of inosine and hypoxanthine in human plasma from healthy volunteers and patients presenting with potential acute cardiac ischemia. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854(1-2):158-64. doi: 10.1016/j.jchromb.2007.04.013.
31. Al-Shamiri SA, Hasan NA, Frankul WM, Al-Hamdi AT. Purines and oxypurines in myocardial ischemia. Saudi Med J. 2009;30(2):257-66.
32. Kristensen AMD, Pareek M, Kragholm KH, Sehested TSG, Olsen MH, Prescott EB. Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons. Cardiology. 2022;147(3):235-247. doi: 10.1159/000524948.
33. Ralapanawa U, Kumarasiri PVR, Jayawickreme KP, Kumarihamy P, Wijeratne Y, Ekanayake M, Dissanayake C. Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka. BMC Cardiovasc Disord. 2019;19(1):229. doi: 10.1186/s12872-019-1217-x.
34. Wu M, Yang S, Liu G, Gu C, Ren P, Zhao R, Zhao Y, Xing Y, Liu L, Liang J. Treating unstable angina with detoxifying and blood-activating formulae: A randomized controlled trial. J Ethnopharmacol. 2021;281:114530. doi: 10.1016/j.jep.2021.114530.
35. Bäckström T, Goiny M, Lockowandt U, Liska J, Franco-Cereceda A. Cardiac outflow of amino acids and purines during myocardial ischemia and reperfusion. J Appl Physiol (1985). 2003;94(3):1122-8. doi: 10.1152/japplphysiol.00138.2002.
36. Szabó G, Stumpf N, Radovits T, Sonnenberg K, Gerö D, Hagl S, Szabó C, Bährle S. Effects of inosine on reperfusion injury after heart transplantation. Eur J Cardiothorac Surg. 2006;30(1):96-102. doi: 10.1016/j.ejcts.2006.04.003.
37. Takahashi-Sato K, Murakawa M, Kimura J, Ito MA, Matsuoka I. Loss of ectonucleotidases from the coronary vascular bed after ischemia-reperfusion in isolated rat heart. BMC Cardiovasc Disord. 2013;13:53. doi: 10.1186/1471-2261-13-53.
38. García-Villalón AL, Monge L, Fernández N, Salcedo A, Narváez-Sánchez R, Diéguez G. Coronary response to diadenosine pentaphosphate after ischaemia-reperfusion in the isolated rat heart. Cardiovasc Res. 2009;81(2):336-43. doi: 10.1093/cvr/cvn321.
39. Stavrou BM, Beck C, Flores NA. Changes in extracellular pH and myocardial ischaemia alter the cardiac effects of diadenosine tetraphosphate and pentaphosphate. Br J Pharmacol. 2001;134(3):639-47. doi: 10.1038/sj.bjp.0704288.
40. Luo J, Jankowski V, Güngär N, Neumann J, Schmitz W, Zidek W, Schlüter H, Jankowski J. Endogenous diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate in human myocardial tissue. Hypertension. 2004;43(5):1055-9. doi: 10.1161/01.hyp.0000126110.46402.dd.
41. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576-85. doi: 10.1038/nm.3145.
42. Koeth RA, Lam-Galvez BR, Kirsop J, Wang Z, Levison BS, Gu X, Copeland MF, Bartlett D, Cody DB, Dai HJ, Culley MK, Li XS, Fu X, Wu Y, Li L, DiDonato JA, Tang WHW, Garcia-Garcia JC, Hazen SL. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 2019;129(1):373-387. doi: 10.1172/JCI94601.
43. Claus SP. Mammalian-microbial cometabolism of L-carnitine in the context of atherosclerosis. Cell Metab. 2014;20(5):699-700. doi: 10.1016/j.cmet.2014.10.014.
44. Zhao Y, Yang N, Gao J, Li H, Cai W, Zhang X, Ma Y, Niu X, Yang G, Zhou X, Li Y. The Effect of Different l-Carnitine Administration Routes on the Development of Atherosclerosis in ApoE Knockout Mice. Mol Nutr Food Res. 2018;62(5). doi: 10.1002/mnfr.201700299.
45. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30-41. doi: 10.1196/annals.1320.003.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |